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694Objectives: Controversy exists regarding the importance of circulating antibodies as determined by panel-
reactive antibody screening as a risk factor for graft failure in pediatric patients undergoing heart transplantation.
This study sought to determine the association of elevated anti-human leukocyte antibodies with long-term
survival in pediatric heart transplant patients.
Methods: The United Network for Organ Sharing registry was queried for pediatric patients (aged<18 years at
listing) with panel-reactive antibody levels obtained before heart transplantation from 1987 through 2004.
Survival analysis methods were used to assess the association of elevated panel-reactive antibodies with long-
term graft and patient survival.
Results: Panel-reactive antibodies were obtained before transplantation from 3534 patients, median age 4 years
(interquartile range 0–12 years). Most, 2711 (77%), had no detectible panel-reactive antibodies, 436 (12%) had
panel-reactive antibodies of 1% to 10%, and 387 (11%) had panel-reactive antibodies greater than 10%. Patients
with panel-reactive antibodies greater than 10% were more likely to be older (P ¼ .04), have congenital heart
disease (P< .001), and have a longer wait list time (P ¼ .006). Patients with panel-reactive antibodies greater
than 10% had significantly worse graft survival and patient survival than did patients with undetectable panel-
reactive antibodies and panel-reactive antibodies of 1% to 10% (P< .05 for all). Controlling for confounding
variables, elevated panel-reactive antibodies as a continuous variable and panel-reactive antibodies greater
than 10% as a categorical variable were independently associated with decreased graft survival (P ¼ .04 and
P ¼ .02, respectively).
Conclusions: Elevated panel-reactive antibodies are independently associated with worse long-term graft
survival in pediatric patients undergoing heart transplantation. Further study is needed to determine the optimal
management of this high-risk population. (J Thorac Cardiovasc Surg 2010;140:694-9)Supplemental material is available online.
Heart transplantation in children is routinely performed in
many institutions with excellent short- and medium-term
survival.1,2 Long-term survival is still somewhat limited,
with the median survival after transplantation being 11 to
16 years, depending on the age at transplant.3 Many
pretransplant factors have limited posttransplant survival,e Department of Pediatrics, Lillie Frank Abercrombie Section of Pediatric
ology,a and the Michael E. DeBakey Department of Surgery,b Baylor College
dicine, Texas Children’s Hospital, Houston, Tex.
res: None.
d for publication Nov 24, 2009; revisions received March 24, 2010; accepted
blication April 12, 2010; available ahead of print May 31, 2010.
for reprints: Joseph W. Rossano, MD, Lillie Frank Abercrombie Section of
tric Cardiology, Texas Children’s Hospital, 6621 Fannin; MC 19345-C,
ton, TX 77030 (E-mail: jrossano@bcm.tmc.edu).
23/$36.00
ht  2010 by The American Association for Thoracic Surgery
016/j.jtcvs.2010.04.009
The Journal of Thoracic and Cardiovascular Surgincluding the presence of congenital heart disease, renal in-
sufficiency, and the use of extracorporeal life support.3 Ad-
ditionally, the presence of antibodies directed against human
leukocyte antigens (HLA) has been found to be associated
with decreased survival in adults.4-7
However, there are very limited data on the effect of anti-
HLA antibodies on survival after pediatric heart transplanta-
tion, and the available reports yield conflicting results.
Several studies have demonstrated an increased risk of acute
rejection among patients with elevated pretransplant anti-
HLA antibodies,8,9 but others have not.10 Additionally, there
has been some suggestion of decreased survival in this
cohort of patients11,12; however, this finding has not been
consistent.10,13 The lack of consistent findings from these
studies may be, in part, due to each study being a single
center study of relatively small size.
Anti-HLA antibodies are typically measured in pretrans-
plant patients with panel of reactive antibody (PRA) testing.
PRA testing involves testing the potential recipient’s serum
against a panel of HLA antigens, either from lymphocytes or
from purified HLA antigens.14 The results of PRA testingery c September 2010
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
HLA ¼ human leukocyte antigen
PRA ¼ panel-reactive antibody
UNOS ¼ United Network for Organ Sharing
STAR ¼ Standard Transplant Analysis and
Research
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Rossano et al Cardiothoracic Transplantationare expressed as a percentage of reactivity. Conventionally,
a PRA value of more than 10% is thought to be sensitive for
identifying patients at increased risk for adverse out-
comes.7,15
The United Network for Organ Sharing (UNOS) main-
tains a database of all solid organ transplants in the United
States. Data on pretransplant factors, including PRA levels,
are recorded as are outcome data including graft and patient
survival. Using the UNOS database, this study aimed to test
the hypothesis that elevated pretransplant PRAs would be
a risk factor for long-term graft and patient survival in
pediatric patients undergoing heart transplantation.T
XMETHODS
A retrospective analysis was performed on data obtained from the UNOS
Standard Transplant Analysis and Research (STAR) files, with additional
data provided by UNOS on crossmatch results. Data on heart transplants
in the United States from October 1, 1987, with follow-up through May
15, 2008, were included for analysis. PRA data, expressed as a percentage,
were available for transplants through June 1, 2004. Data were not available
during that time period on the specific percentages of PRAs for HLA class I
or class II antigens. The database was queried for pediatric patients
(<18 years old at time of listing for heart transplantation) who underwent
heart transplantation from October 1, 1987, through June 1, 2004, with
PRA data before transplantation.
The most recent PRAs before transplantation were used for analysis. Pa-
tients were placed into 3 groups, 0%, 1% to 10%, or more than 10%
PRAs. Additional data evaluated included demographic information, indi-
cation for transplantation, patient condition at transplantation including the
use of inotropic medications or extracorporeal membrane oxygenation
(ECMO), donor information, patient survival, and graft survival. The pri-
mary end point was graft survival and the secondary end point was patient
survival.
Statistical Analysis
Data from the UNOS STAR files were imported into SPSS, version 16.0
(SPSS Inc, Chicago, Ill), for analysis. Baseline data are reported as means
with standard deviations or as percentages, as appropriate. Baseline charac-
teristics were compared among the 3 groups using an analysis of variance
with the Bonferroni adjustment for multiple comparisons for continuous
variables and a contingency table analysis for categorical variables.
Kaplan–Meier survival curves were constructed and log–rank statistics
were used to compare overall graft and patient survival among the different
PRA groups. Cox proportional hazards models were used to assess the
hazard ratios of graft and patient death in patients with elevated PRAs,
while controlling for age, gender, diagnosis, year of transplant, inotropic
medication at transplant, ECMO at transplant, mechanical ventilation atThe Journal of Thoracic and Catransplant, donor age, donor weight, donor weight/recipient weight ratio,
ischemic time, donor/recipient cytomegalovirus status, and crossmatch sta-
tus. For the multivariable analysis, values of missing variables were re-
placed by the most common variable for categorical variables and the
median value for continuous variables, as has been done previously.16RESULTS
A total of 4176 pediatric patients underwent heart trans-
plantation during the study period (1987–2004) with PRA
data available for 3534 (85%). Patients with PRA data
were older, weighed more, and waited longer for transplan-
tation than patients without PRA data (Table E1)Most, 2711
(77%), had no detectible PRAs, 436 (12%) had PRAs of
1% to 10%, and 387 (11%) had PRAs greater than 10%.
Patients with PRAs greater than 10% were more likely to
be older, heavier, have congenital heart disease, be on ino-
tropic support at transplant, wait longer for transplant, and
have heavier donors (P< .05 for all) (Table 1). Evaluation
of PRA level by age group demonstrated PRAs greater
than 10% in 10% of patients aged 0 to 5 years, 12.4% of
patients aged 6 to 13 years, and 11.8% of patients 13 years
of age or older (Figure E1). Patients with PRAs greater than
10% were also more likely to have a positive crossmatch
(P< .001) (Table 2).
Long-term graft survival was significantly less in patients
with PRAs greater than 10%, median survival 7.1 years
(interquartile range [IQR] 5.6–8.5 years), than in patients
with PRAs of 1% to 10%, median survival 9.6 years
(IQR 7.8–11.4 years) (P¼ .003), and patients with undetect-
able PRAs, median survival 9.8 years (IQR 9.1–10.4 years)
(P¼ .001). Graft survival was not different between patients
with undetectable PRAs and those with PRAs of 1% to 10%
(P ¼ .75). Patient survival was also significantly less in pa-
tients with PRAs greater than 10%, median survival 10.3
years (IQR 7.5–13.2 years), than in patients with PRAs of
1% to 10%, median survival 13.9 (IQR 11.0–16.8 years)
(P¼ .04), and patients with undetectable PRAs, median sur-
vival 12.9 years (IQR 11.6–14.3 years) (P ¼ .014). Patient
survival was also not significantly different between patients
with PRAs of 1% to 10% and those with undetectable PRAs
(P ¼ .94) (Figure 1). Among patients with elevated PRAs
greater than 10%, survival was similar to that of patients
with PRAs of 11% to 25%, 26% to 50%, and more than
50% (Figure E2).
A positive crossmatch was found in 320 (9%) patients.
Patients with PRAs greater than 10% and a positive cross-
match had the worst overall graft and patient survival, which
was significantly worse than that of patients with PRAs of
10% or less and a negative crossmatch (P< .05 for both)
(Figure 2). Patients with PRAs greater than 10%with a neg-
ative crossmatch had worse graft and patient survival than
did patients with PRAs of 10% or less; however, statistical
significance was only reached for graft survival in patients
with PRAs of 10% or less and a negative crossmatch.rdiovascular Surgery c Volume 140, Number 3 695
TABLE 1. Patient characteristics
Characteristic Undetectable PRA (n ¼ 2711) PRA 1%–10% (n ¼ 436) PRA>10% (n ¼ 387) P value
Age, y 6.2  6.3y 6.6  6.2 7.1  6.2y .043
Weight, kg 24.4  23.9y 25.4  24.0 27.2  23.9y .043
Female 1174 (43) 178 (41) 165 (43) .620
Year of transplant <.001
1987–1992 634 (79) 110 (14) 58 (7)
1992–1998 1115 (77) 196 (14) 136 (9)
1999–2004 962 (75) 130 (10) 193 (15)
Diagnosis <.001
Congenital heart disease 1262 (47) 190 (44) 200 (52)
Cardiomyopathy 1243 (46) 199 (46) 115 (30)
Other 206 (8) 47 (12) 72 (19)
Inotropic support* 875 (32) 133 (31) 157 (41) .003
ECMO* 131 (5) 14 (3) 15 (4) .258
Mechanical ventilation* 524 (19) 82 (19) 75 (19) .966
Wait list time, mo 2.3  4.6y 2.5  5.7 3.5  5.8y .006
Data are shown as mean  SD or n (%). ECMO, Extracorporeal membrane oxygenation. *Support at time of transplantation. yDifference between groups P< .05.
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independently associated with decreased graft survival
(P ¼ .02) (Table 3). When we evaluated PRAs as a continu-
ous variable, elevated PRAs were independently associated
with decreased graft survival (P ¼ .04). PRAs were not
independently associated with patient survival.
DISCUSSION
This is the first study to demonstrate the incidence and out-
come of a large cohort of pediatric patients with elevated pre-
transplant anti-HLA antibodies. More than 75% of patients
had no detectable PRAs whereas 11% had PRAs elevated
more than 10%. Prior studies from adult patients have deter-
mined that risk factors for the development of anti-HLA an-
tibodies include pregnancy, prior exposure to blood products
or allograft material, prior transplant, and being on mechan-
ical circulatory support.17 Similarly, our findings suggest
that pediatric patients with elevated PRAs were more likely
to be older and have congenital heart disease, many of
whom would have undergone prior cardiac surgery with
a risk of exposure to blood products and allograft material.
Additionally, patients undergoing transplantation in the
most recent era (1999–2004) had more than twice the inci-
dence of elevated PRAs as patients in the earliest era
(1987–1992). This is likely related, in part, to techniquesTABLE 2. Donor and transplant characteristics
Characteristic Undetectable PRA (n ¼ 271
Donor age, y 9.0  10.9
Donor weight, kg 29.4  24.3*
Donor/recipient weight ratio 1.5  1.1
Ischemic time, h 3.6  1.3
Crossmatch positive 155 (6)y
Donor CMV positive 471 (17)
Donor CMV positive/recipient CMV negative 98 (4)
Data are shown as mean  SD or n (%). CMV, Cytomegalovirus. *Difference between gr
696 The Journal of Thoracic and Cardiovascular Surgused for PRA measurement, which have changed over
time. Complement-dependent cytoxicity assay was likely
used virtually exclusively in the early era and has been re-
placed in most centers by more sensitive techniques such
as flow cytometry.17 In addition, the complexity of patients
at high risk for PRA development, such as patients undergo-
ing transplantation after failed Fontan palliation and patients
undergoing retransplantation, has also increased over
time.3,18 Importantly, year of transplant was controlled for
in the multivariable analysis and elevated PRA remained
independently associated with worse graft survival.
We did not find an increased risk of elevated PRAs among
patients supported with ECMO. Yang and associates19 re-
ported previously that 3 (31%) of 13 pediatric transplant pa-
tients supported by ECMO had elevated PRAs, but elevated
PRAs did not develop in any additional patients receiving
ECMO support. Whether the shorter duration of support
for pediatric patients on extracorporeal life support as
a bridge to transplantation as opposed to adults on left ven-
tricular assist devices accounts for these differences or
whether other factors may contribute to this finding merits
future inquiry.
Importantly, patients with elevated antibodies as deter-
mined by greater than 10% PRAs had significantly worse
overall patient and graft survival. Those with undetectable1) PRA 1%–10% (n ¼ 436) PRA>10% (n ¼ 387) P value
9.4  10.9 10.2  11.0 .110
31.5  25.7 33.0  25.3* .016
1.5  0.9 1.4  0.7 .225
3.5  1.4 3.5  1.4 .387
34 (8)z 131 (34)y z <.001
72 (17) 67 (17) .967
10 (2) 8 (2) .130
oups P<.05. y and z indicate difference between groups P< .001.
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FIGURE 1. Kaplan–Meier survival curve with log–rank statistics for graft and patient survival. PRA, Panel-reactive antibody.
Rossano et al Cardiothoracic TransplantationPRAs had a median graft survival over 2.5 years longer than
those with PRAs greater than 10%. Additionally, those with
PRAs greater than 10% were significantly more likely to
have a positive crossmatch. Although the presence of a posi-
tive crossmatch shortened graft and patient survival, patients
with elevated PRAs and a negative crossmatch still had
worse graft survival than patients without elevated PRAs
and a negative crossmatch. It is important to note that the sur-
vival in patients with a positive crossmatch and low PRAs
was similar to that of patients with a negative crossmatch
and high PRAs. These findings are consistent with the con-
cept that patients with elevated PRAs may have shortened
graft survival even in the setting of a negative crossmatch.
The association of PRA elevation greater than 10% and
worse graft survival were independent of pretransplant sta-
tus, year of transplantation, donor factors, crossmatch status,
and rejection episodes in the first year after transplant. It is
also important to note that the survival of patients with
PRAs of 0% to 10% was virtually identical to that of
patients with undetectable PRAs.FIGURE 2. Kaplan–Meier survival curve with log–rank statistics for graft a
The Journal of Thoracic and CaPrior pediatric studies have been limited by the small
number of patients with elevated PRA levels, 8-13 thus
limiting the power of these studies to detect important
differences in long-term survival. Feingold and colleagues13
described 36 patients with PRAs greater than 10% and
found that patients with elevated PRAs had a decreased free-
dom from coronary allograft vasculopathy, but no statisti-
cally significant difference in survival. Holt and
coworkers9 described the outcomes of 17 patients who un-
derwent transplantation with PRAs greater than 10%. This
cohort had a high incidence of rejection (92%), a 1-year sur-
vival of 85%, and a 3-year survival of 73%. There was no
control group of patients with lower PRAs for this study,
but the rates of rejection are higher and survival lower
than recent cohorts from the International Society for Heart
and Lung Transplantation.3 The current study is benefited by
including more than 3500 pediatric patients with a long du-
ration of follow-up, which allowed for clinically important
differences to be detected. Furthermore, this study
strengthens the notion that pediatric patients sensitizednd patient survival by crossmatch status. PRA, Panel-reactive antibody.
rdiovascular Surgery c Volume 140, Number 3 697
T
X
TABLE 3. Cox proportional hazard models of graft and patient
survival
Hazard ratio (95% CI) P value
Graft survival
PRAs>10% 1.196 (1.025–1.396) .02
PRAs, continuous variable 1.003 (1.000–1.006) .04
Patient survival
PRAs>10% 1.128 (0.95– 1.339) .17
PRAs, continuous variable 1.002 (0.999–1.005) .27
CI, Confidence interval.
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creased risk for earlier graft failure. The precise mechanism
by which increased PRAs lead to earlier graft failure are
likely multifaceted, including an increased likelihood of
a positive crossmatch,20 early graft dysfunction,21 acute re-
jection,15,21-24 and the earlier development of coronary
allograft vasculopathy.13,15Limitations
This study has several limitations. Data on different tech-
niques for measuring PRAs were not assessed, and thus
whether different threshold percentages for PRAs should
be used with different techniques cannot be determined.
Likewise, the more sensitive tests such as flow cytometry
or Luminex,24 may detect some antibodies that, while pres-
ent, are not clinically important.25 Finally, data were not
available on different patient management strategies such
as the use of a prospective crossmatch, the use of a virtual
crossmatch, or antibody reduction strategies.26 Data were
also not available on patients who did not survive to trans-
plantation. Although the study is benefited by the large num-
ber of patients included and long duration of follow-up data,
patient management likely varied considerably among dif-
ferent centers and over time. This variation could affect out-
come, and given the limitations of the database, could not be
completely controlled for in the multivariable models used.CONCLUSIONS
The majority of pediatric heart transplant patients do not
have elevated PRAs before transplantation. PRAs greater
than 10% are more common in patients who are older,
have congenital heart disease, and are receiving inotropic
support at transplant. Elevations in PRAs greater than
10% are independently associated with worse long-term
graft survival in pediatric heart transplant patients. Further
study is needed to determine the optimal management of
this high-risk population.
We would like to acknowledge the contribution of E. O’Brian
Smith, PhD, for his assistance with the statistical analysis. The
data reported here have been supplied by the United Network of Or-
gan Sharing on May 20, 2008, as the contractor for the Organ Pro-
curement and Transplantation Network (OPTN). The interpretation698 The Journal of Thoracic and Cardiovascular Surgand reporting of these data are the responsibility of the authors and
in no way should be seen as an official policy of or interpretation by
the OPTN or the U.S. Government.References
1. Morales DL, Dreyer WJ, Denfield SW, Heinle JS, McKenzie ED, Graves DE,
et al. Over two decades of pediatric heart transplantation: how has survival
changed? J Thorac Cardiovasc Surg. 2007;133:632-9.
2. Ross M, Kouretas P, Gamberg P, Miller J, Burge M, Reitz B, et al. Ten- and
20-year survivors of pediatric orthotopic heart transplantation. J Heart Lung
Transplant. 2006;25:261-70.
3. Kirk R, Edwards LB, Aurora P, Taylor DO, Christie J, Dobbels F, et al. Registry
of the International Society for Heart and Lung Transplantation: eleventh official
pediatric heart transplantation report—2008. J Heart Lung Transplant. 2008;27:
970-7.
4. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA,
Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in
8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007;84:
1556-62; discussion 62–63.
5. Przybylowski P, Balogna M, Radovancevic B, Frazier OH, Susskind B,
Van Buren C, et al. The role of flow cytometry-detected IgG and IgM
anti-donor antibodies in cardiac allograft recipients. Transplantation.
1999;67:258-62.
6. Bishay ES, Cook DJ, El Fettouh H, Starling RC, Young JB, Smedira NG, et al.
The impact of HLA sensitization and donor cause of death in heart transplantation.
Transplantation. 2000;70:220-2.
7. Kobashigawa JA, Sabad A, Drinkwater D, Cogert GA, Moriguchi JD, Kawata N,
et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for
poor outcome after cardiac transplantation? Circulation. 1996;94(9 Suppl):
II294-7.
8. Di Filippo S, Girnita A, Webber SA, Tsao S, Boyle GJ, Miller SA, et al. Impact of
ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome.
Hum Immunol. 2005;66:513-8.
9. Holt DB, Lublin DM, Phelan DL, Boslaugh SE, Gandhi SK, Huddleston CB, et al.
Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with
a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic
therapy. J Heart Lung Transplant. 2007;26:876-82.
10. Wright EJ, Fiser WP, Edens RE, Frazier EA, MorrowWR, Imamura M, et al. Car-
diac transplant outcomes in pediatric patients with pre-formed anti-human leuko-
cyte antigen antibodies and/or positive retrospective crossmatch. J Heart Lung
Transplant. 2007;26:1163-9.
11. Jacobs JP, Quintessenza JA, Boucek RJ, Morell VO, Botero LM, Badhwar V,
et al. Pediatric cardiac transplantation in children with high panel reactive anti-
body. Ann Thorac Surg. 2004;78:1703-9.
12. Pollock-BarZiv SM, den Hollander N, Ngan BY, Kantor P, McCrindle B,
Dipchand AI, et al. Pediatric heart transplantation in human leukocyte antigen
sensitized patients: evolving management and assessment of intermediate-term
outcomes in a high-risk population. Circulation. 2007;116(11 Suppl):I172-8.
13. Feingold B, Bowman P, Zeevi A, Girnita AL, Quivers ES, Miller SA, et al. Sur-
vival in allosensitized children after listing for cardiac transplantation. J Heart
Lung Transplant. 2007;26:565-71.
14. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ
transplantation. Transplantation. 2000;69:319-26.
15. Kerman RH, Susskind B, Kerman D, LamM, Gerolami K,Williams J, et al. Com-
parison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive anti-
body to identify alloreactivity in pretransplantation sera of heart transplant
recipients: correlation to rejection and posttransplantation coronary artery disease.
J Heart Lung Transplant. 1998;17:789-94.
16. Patlolla V, Patten RD, Denofrio D, Konstam MA, Krishnamani R. The effect of
ventricular assist devices on post-transplant mortality: an analysis of the United
Network for Organ Sharing thoracic registry. J Am Coll Cardiol. 2009;53:264-71.
17. Mehra MR, Uber PA, Uber WE, Scott RL, Park MH. Allosensitization in heart
transplantation: implications and management strategies. Curr Opin Cardiol.
2003;18:153-8.
18. Bernstein D, Naftel D, Chin C, Addonizio LJ, Gamberg P, Blume ED, et al. Out-
come of listing for cardiac transplantation for failed Fontan: a multi-institutional
study. Circulation. 2006;114:273-80.
19. Yang J, Schall C, Smith D, Kreuser L, Zamberlan M, King K, et al. HLA sensi-
tization in pediatric pre-transplant cardiac patients supported by mechanical assist
devices: the utility of Luminex. J Heart Lung Transplant. 2009;28:123-9.ery c September 2010
Rossano et al Cardiothoracic Transplantation20. Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH. The effect of panel
reactive antibodies and the donor specific crossmatch on graft survival after heart
and heart-lung transplantation. Transpl Immunol. 1993;1:60-5.
21. Lavee J, Kormos RL, Duquesnoy RJ, Zerbe TR, Armitage JM, Vanek M, et al.
Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival af-
ter heart transplantation. J Heart Lung Transplant. 1991;10:921-9; discussion 9–30.
22. Itescu S, Tung TC, Burke EM, Weinberg A, Moazami N, Artrip JH, et al. Pre-
formed IgG antibodies against major histocompatibility complex class II antigens
are major risk factors for high-grade cellular rejection in recipients of heart trans-
plantation. Circulation. 1998;98:786-93.
23. DeNofrio D, Rho R, Morales FJ, Kamoun M, Kearns J, Dorozinsky C, et al. De-
tection of anti-HLA antibody by flow cytometry in patients with a left ventricularThe Journal of Thoracic and Caassist device is associated with early rejection following heart transplantation.
Transplantation. 2000;69:814-8.
24. Tambur AR, Bray RA, Takemoto SK, Mancini M, Costanzo MR,
Kobashigawa JA, et al. Flow cytometric detection of HLA-specific anti-
bodies as a predictor of heart allograft rejection. Transplantation. 2000;
70:1055-9.
25. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, Luminex binding
antibodies—a new tool for prediction of graft failure after heart transplantation.
Am J Transplant. 2007;7:2809-15.
26. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al.
Rituximab and intravenous immune globulin for desensitization during renal
transplantation. N Engl J Med. 2008;359:242-51.rdiovascular Surgery c Volume 140, Number 3 699
T
X
FIGURE E1. Panel-reactive antibody level by age group. PRA, Panel-reactive antibody.
FIGUREE2. Kaplan–Meier survival curve with log–rank statistics for graft and patient survival with panel-reactive antibody levels greater than 10%. PRA,
Panel reactive antibody.
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TABLE E1. Characteristics of patients with and without PRA data
Characteristic No PRA data (n ¼ 642) PRA data (n ¼ 3534) P value
Age, y 5.6  6.2 6.6  6.2 .04
Weight, kg 22.0  22.6 25.2  23.7 .004
Female 285 (44) 1517 (43) .49
Year of transplant <.001
1987–1992 196 (20) 802 (80)
1993–1998 183 (11) 1447 (88)
1999–2004 263 (17) 1285 (83)
Diagnosis .048
Congenital heart disease 324 (50) 1652 (47)
Cardiomyopathy 276 (43) 1557 (44)
Other 42 (7) 325 (9)
ECMO* 31 (5) 160 (5) .74
Mechanical ventilation* 141 (22) 681 (19) .11
Wait list time, mo 2.1  5.2 2.6  5.0 .02
Data are shown as mean  SD or n (%). PRA, Panel-reactive antibody; ECMO, extracorporeal membrane oxygenation. *Support at time of transplantation.
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